Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
CompletedNCT01649557
Safety study of OPC-34712 in schizophrenia
This study is completed in the United States, in Bulgaria, in Croatia, .... It is testing OPC-34712 for schizophrenia.
SchizophreniaDrugFrom 18 Years to 67 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
Check the study details
Check the official source, then confirm these points with the research team.
View official study record (opens in a new tab)
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateAugust 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 244
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Croatia, ...
- Age range
- From 18 Years to 67 Years
- Official registry ID
- NCT01649557
- Official title
- A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients With Schizophrenia
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01649557. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
View official study record (opens in a new tab)The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Bulgaria · 6 sites
- Otsuka Investigational SiteBurgasSite status: Not listed — confirm with the team
- Otsuka Investigational SiteKazanlakSite status: Not listed — confirm with the team
- Otsuka Investigational SitePazardzhikSite status: Not listed — confirm with the team
- Otsuka Investigational SitePlovdivSite status: Not listed — confirm with the team
- Otsuka Investigational SiteRadnevoSite status: Not listed — confirm with the team
- Otsuka Investigational SiteRousseSite status: Not listed — confirm with the team
Croatia · 2 sites
- Otsuka Investigational SiteRijekaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteZagrebSite status: Not listed — confirm with the team
India · 9 sites
- Otsuka Investigational SiteVijaywada, Andh PradSite status: Not listed — confirm with the team
- Otsuka Investigational SiteVisakhapatnam, Andh PradSite status: Not listed — confirm with the team
- Otsuka Investigational SiteAhmedabad, GujaratSite status: Not listed — confirm with the team
- Otsuka Investigational SiteBangalore, KarnaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteMangalore, KarnaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteMangalore, KarnaSite status: Not listed — confirm with the team
- Otsuka Investigational SitePune, MaharaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteChennai, Tamil NaduSite status: Not listed — confirm with the team
- Otsuka Investigational SiteVaranasi, Uttar PradSite status: Not listed — confirm with the team
Philippines · 2 sites
- Otsuka Investigational SiteCebu CitySite status: Not listed — confirm with the team
- Otsuka Investigational SiteMandaluyongSite status: Not listed — confirm with the team
Romania · 5 sites
- Otsuka Investigational SiteAradSite status: Not listed — confirm with the team
- Otsuka Investigational SiteBucharestSite status: Not listed — confirm with the team
- Otsuka Investigational SiteBucharestSite status: Not listed — confirm with the team
- Otsuka Investigational SiteCluj-NapocaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteOradeaSite status: Not listed — confirm with the team
Russia · 6 sites
- Otsuka Investigational SiteMoscowSite status: Not listed — confirm with the team
- Otsuka Investigational SiteMoscow RegionSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSaint PetersburgSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSaint PetersburgSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSaint PetersburgSite status: Not listed — confirm with the team
- Otsuka Investigational SiteZagorodnoyeSite status: Not listed — confirm with the team
Serbia · 3 sites
- Otsuka Investigational SiteBelgradeSite status: Not listed — confirm with the team
- Otsuka Investigational SiteKragujevacSite status: Not listed — confirm with the team
- Otsuka Investigational SiteNoviSadSite status: Not listed — confirm with the team
Slovakia · 5 sites
- Otsuka Investigational SiteBojniceSite status: Not listed — confirm with the team
- Otsuka Investigational SiteBratislavaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteLiptovský MikulášSite status: Not listed — confirm with the team
- Otsuka Investigational SiteRimavská SobotaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteŽilinaSite status: Not listed — confirm with the team
South Korea · 4 sites
- Otsuka Investigational SiteChuncheonSite status: Not listed — confirm with the team
- Otsuka Investigational SiteIncheonSite status: Not listed — confirm with the team
- Otsuka Investigational SiteIncheonSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSeoulSite status: Not listed — confirm with the team
Taiwan · 2 sites
- Otsuka Investigational SiteHualien CitySite status: Not listed — confirm with the team
- Otsuka Investigational SiteTaipeiSite status: Not listed — confirm with the team
Ukraine · 8 sites
- Otsuka Investigational SiteChernihivSite status: Not listed — confirm with the team
- Otsuka Investigational SiteDnipropetrovskSite status: Not listed — confirm with the team
- Otsuka Investigational SiteKyivSite status: Not listed — confirm with the team
- Otsuka Investigational SiteKyivSite status: Not listed — confirm with the team
- Otsuka Investigational SiteKyivSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSimferopolSite status: Not listed — confirm with the team
- Otsuka Investigational SiteStepanovkaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteVinnytsiaSite status: Not listed — confirm with the team
United States · 16 sites
- Otsuka Investigational SiteLittle Rock, ArkansasSite status: Not listed — confirm with the team
- Otsuka Investigational SiteEscondido, CaliforniaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteGarden Grove, CaliforniaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteLong Beach, CaliforniaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteOceanside, CaliforniaSite status: Not listed — confirm with the team
- Otsuka Investigational SitePasadena, CaliforniaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSan Diego, CaliforniaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSan Diego, CaliforniaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSanta Ana, CaliforniaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteWashington D.C., District of ColumbiaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteBradenton, FloridaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteMaitland, FloridaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteSt Louis, MissouriSite status: Not listed — confirm with the team
- Otsuka Investigational SiteCedarhurst, New YorkSite status: Not listed — confirm with the team
- Otsuka Investigational SitePhiladelphia, PennsylvaniaSite status: Not listed — confirm with the team
- Otsuka Investigational SiteAustin, TexasSite status: Not listed — confirm with the team
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving OPC-34712. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 67 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., which appears to be a pharmaceutical company. Sponsor website: https://www.otsuka.co.jp/en/. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedEUCTR 2011-004790-90
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedEUCTR 2016-000061-23
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.